Kilburn Jeremy M, Ellis Thomas L, Lovato James F, Urbanic James J, Bourland J Daniel, Munley Michael T, Deguzman Allan F, McMullen Kevin P, Shaw Edward G, Tatter Stephen B, Chan Michael D
Department of Radiation Oncology, Wake Forest School of Medicine, 1 Medical Center Blvd, Winston-Salem, NC, 27157, USA,
J Neurooncol. 2014 Mar;117(1):167-74. doi: 10.1007/s11060-014-1373-x. Epub 2014 Feb 7.
Gamma Knife Radiosurgery (GKRS) has been reported in the treatment of brainstem metastases while dose volume toxicity thresholds remain mostly undefined. A retrospective review of 52 brainstem metastases in 44 patients treated with GKRS was completed. A median dose of 18 Gy (range 10-22 Gy) was prescribed to the tumor margin (median 50 % isodose). 25 patients had undergone previous whole brain radiation therapy. Toxicity was graded by the LENT-SOMA scale. Mean and median follow-up was 10 and 6 months. Only 3 of the 44 patients are living. Multiple brain metastases were treated in 75 % of patients. Median size of lesions was 0.134 cc, (range 0.013-6.600 cc). Overall survival rate at 1 year was 32 % (95 % CI 51.0-20.1 %) with a median survival time of 6 months (95 % CI 5.0-16.5). Local control rate at 6 months and 1 year was 88 % (95 % CI 70-95 %) and 74 % (95 % CI 52-87 %). Cause of death was neurologic in 17 patients, non-neurologic in 20 patients, and unknown in four. Four patients experienced treatment related toxicities. Univariate analysis of tumor volume revealed that volume greater than 1.0 cc predicted for toxicity. A strategy of using lower marginal doses with GKRS to brain stem metastases appears to lead to a lower local control rate than seen with lesions treated within the standard dose range in other locations. Tumor size greater than 1.0 cc predicted for treatment-related toxicity.
伽玛刀放射外科手术(GKRS)已被报道用于治疗脑干转移瘤,然而剂量体积毒性阈值大多仍未明确。对44例接受GKRS治疗的患者的52个脑干转移瘤进行了回顾性研究。肿瘤边缘(中位50%等剂量线)的处方中位剂量为18 Gy(范围10 - 22 Gy)。25例患者曾接受过全脑放射治疗。毒性按照LENT - SOMA量表分级。平均和中位随访时间分别为10个月和6个月。44例患者中仅3例存活。75%的患者有多发性脑转移瘤。病变的中位大小为0.134 cc(范围0.013 - 6.600 cc)。1年总生存率为32%(95%CI 51.0 - 20.1%),中位生存时间为6个月(95%CI 5.0 - 16.5)。6个月和1年的局部控制率分别为88%(95%CI 70 - 95%)和74%(95%CI 52 - 87%)。17例患者死于神经系统原因,20例死于非神经系统原因,4例死因不明。4例患者出现与治疗相关的毒性反应。对肿瘤体积的单因素分析显示,体积大于1.0 cc预示着毒性反应。与在其他部位标准剂量范围内治疗的病变相比,采用较低边缘剂量的GKRS治疗脑干转移瘤的策略似乎导致局部控制率较低。肿瘤大小大于1.0 cc预示着与治疗相关的毒性反应。